Abstract
This study was set up to evaluate the costs of a one-stage treatment of chronic osteomyelitis using bioactive glass S53P4 versus a two-stage treatment using gentamicin-loaded PMMA beads. Furthermore, a cost-effectiveness analysis was performed from a hospital's perspective together with the evaluation of clinical outcome. A treatment group (n = 25) receiving one-stage surgery with bioactive glass was retrospectively compared with a two-stage control group (n = 25). An assessment was made of all costs included from first outpatient visit until one year after treatment. Bootstrap simulation and sensitivity analyses were performed. The primary endpoint was cost-effectiveness with clinical outcome as the secondary endpoint. The base case analyses shows dominance of the one-stage treatment with bioactive glass S53P4 due to lower costs and a better clinical outcome. Sensitivity analyses confirm these findings. This study is the first in its kind to show one-stage treatment of chronic osteomyelitis with bioactive glass S53P4 to be cost-effective.
Original language | English |
---|---|
Article number | 3209 |
Number of pages | 11 |
Journal | Materials |
Volume | 12 |
Issue number | 19 |
DOIs | |
Publication status | Published - Oct 2019 |
Keywords
- bioactive glass
- osteomyelitis
- cost-effectivity
- PARENTERAL ANTIMICROBIAL THERAPY
- CALCIUM-PHOSPHATE FORMATION
- IN-VITRO
- ECONOMIC-EVALUATION
- HUMAN OSTEOBLASTS
- JOINT INFECTIONS
- NODULE FORMATION
- IONIC PRODUCTS
- BONE-FORMATION
- BEHAVIOR